FibroGen (FibroGen) Insider Ownership : 5.91 % (As of Apr. 28, 2024)

View and export this data going back to 2014. Start your Free Trial

What is FibroGen Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, FibroGen's insider ownership is 5.91%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, FibroGen's Institutional Ownership is 34.37%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, FibroGen's Float Percentage Of Total Shares Outstanding is 76.01%.

FibroGen Insider Ownership Historical Data

The historical data trend for FibroGen's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Insider Ownership Chart

FibroGen Historical Data

The historical data trend for FibroGen can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Insider Ownership	5.38	5.34	5.79	5.77	5.77	5.74	5.71	5.71	5.91	5.91

FibroGen Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

FibroGen (FibroGen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

FGEN:Mexico 1FG:Germany 1FG:Germany

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Executives

Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno	director, officer: Chief Executive Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig	officer: Chief Commercial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung	officer: SVP, China Operations	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck	director	C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner	officer: Incoming Chief Medical Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham	officer: Chief Financial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr	director	P O BOX 587, WARSAW IN 46581-0587
Pat Controneo	officer: VP, Finance and CFO	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi	director	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158